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Abstract
Drugs currently available for leishmaniasis treatment often show parasite resistance, highly toxic side effects and prohibitive
costs commonly incompatible with patients from the tropical endemic countries. In this sense, there is an urgent need for
new drugs as a treatment solution for this neglected disease. Here we show the development and implementation of an
automated high-throughput viability screening assay for the discovery of new drugs against Leishmania. Assay validation
was done with Leishmania promastigote forms, including the screening of 4,000 compounds with known pharmacological
properties. In an attempt to find new compounds with leishmanicidal properties, 26,500 structurally diverse chemical
compounds were screened. A cut-off of 70% growth inhibition in the primary screening led to the identification of 567
active compounds. Cellular toxicity and selectivity were responsible for the exclusion of 78% of the pre-selected
compounds. The activity of the remaining 124 compounds was confirmed against the intramacrophagic amastigote form of
the parasite. In vitro microsomal stability and cytochrome P450 (CYP) inhibition of the two most active compounds from this
screening effort were assessed to obtain preliminary information on their metabolism in the host. The HTS approach
employed here resulted in the discovery of two new antileishmanial compounds, bringing promising candidates to the
leishmaniasis drug discovery pipeline.
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Introduction
Leishmaniasis is a neglected emerging disease without any
adequate treatment adapted to the field [1]. The disease can be
characterized by skin ulcers (cutaneous leishmaniasis), mucous
degeneration, especially from the mouth and internal nose
(mucocutaneous leishmaniasis), and visceral organ damage
(visceral leishmaniasis), which is lethal if untreated. The different
forms of leishmaniasis manifestation depend mainly on the species
of parasite but are also related to the host immune system. Official
World Health Organization (WHO) numbers from the 1990s are
still used and estimate 12 million infected people and 350 million
at risk living in one of the 88 endemic countries in America,
Europe, Africa, the Middle East and Asia [2]. The number of
deaths as a consequence of leishmaniasis is higher than 50,000 per
year, with an incidence of 1.5 million annual registered cases of the
disfiguring cutaneous leishmaniasis and 0.5 million annual
registered cases of the potentially fatal visceral leishmaniasis [3],
but these numbers probably underestimate the real burden of the
disease [4],[5].
Leishmaniasis is caused by the kinetoplastid species from the
genus Leishmania. Infection takes place when a sandfly vector
inoculates Leishmania promastigotes into the mammalian blood-
stream; these extracellular flagellated forms of the parasite live in
the insect midgut. Once in the bloodstream, parasites are
phagocytosed by mononuclear blood cells, especially macrophag-
es, differentiating into the obligatory intracellular amastigote form.
Amastigotes proliferate inside the macrophages before inducing
the bursting of the host cell and being released into the
bloodstream. This process occurs repeatedly, leading to tissue
damage [6]. Parasite species and the host immune system
determine the clinical status of the disease, ranging from cutaneous
ulcers (cutaneous leishmaniasis) [7] to visceral organ damage
(visceral leishmaniasis) [8], especially of the spleen and the liver.
Most of the antileishmanial drugs currently in use for treatment,
from the long time established antimonials to the recently
introduced miltefosine, have disadvantages, such as patient
toxicity, side effects and/or parasite resistance [9].
Lead discovery is currently one of the bottlenecks in the pipeline
for novel antileishmanial drugs [10]. High-throughput screening
(HTS) optimizes the chance of finding lead compounds through
the identification of active compounds from a large number of
candidates [11–12]. We adapted an in vitro fluorometric assay to
HTS format using the promastigote form of L. major [13], one of
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reference strain used to sequence the genome of this parasite,
completed in 2005 [14], and genome information can be
accessible for future studies, including target identification or
mechanism of action determination. To validate the assay in HTS
format, we screened a 4,000-compound library containing many
bioactive compounds with known pharmacological properties,
including currently used antileishmanials. Following validation,
the assay was applied to the screening of a library containing
26,500 structurally diverse chemical compounds. A total of 567
compounds showing a minimum of 70% growth inhibition of the
parasite (L. major) were identified during the primary screening at
10 mM. Further tests on their cytotoxicity on a human
macrophage cell line and specificity filtering were applied,
resulting in a list of 124 active compounds. To confirm activity
against the intracellular parasites, these 124 compounds were
tested in serial dilutions against L. major amastigotes infecting
THP-1 differentiated macrophages. Through this process, the two
most active compounds with EC50 values lower than 10 mM
against L. major were chosen for further characterization. The 124
active compounds were also tested against intramacrophagic L.
donovani, one of the causative species of visceral leishmaniasis, to
evaluate specificity of the compounds against the parasites causing
different clinical manifestations of the disease. To determine the
quality of the two most active compounds, we tested their
microsomal stability, which would indicate the presence of
metabolites, as well as cytochrome P450 (CYP) inhibition for
drug-drug interaction in multitherapies. The results indicate that
the compounds are good candidates for further characterization
for leishmaniasis therapy. We discuss the relevance of a developed
HTS assay using the promastigote form of the parasite for the
discovery of leishmanicidal compounds and the potential of one of
the selected hits to become a future lead compound against
leishmaniasis.
Methods
Parasites
L. major MHOM/IL/81/FRIEDLIN and L. donovani MHOM/
ET/67/HU3 promastigotes were cultivated at 28uC in axenic
M199 culture medium (Welgene, S. Korea) supplemented with
10% heat-inactivated fetal bovine serum (FBS) (Gibco, United
States) and 1% streptomycin/penicillin (Gibco, United States).
Compound Libraries, Reference Compound and Assay
Plate Preparation
A total of 4,000 small molecules sourced from Sigma, Prestwick
and Tocris were all screened at 2–20 mM, 0.2–2 mM and 0.02–
0.2 mM. The 26,500-compound library screened at 10 mM (in 1%
DMSO) was sourced from TimTec. This small molecule library
contains compounds selected for diversity and drug-like properties
as well as small collections of kinase-focused and protease-focused
compounds. Ethidium bromide (EtBr) (Sigma E1510, United
States), amphotericin B (Sigma A9528, United States), miltefosine
(A.G. Scientific H-1096, United States) and paromomycin sulfate
salt (Sigma P9297, United States) were used as reference
compounds.
Primary Screening Assay: Antileishmanial Activity
After compound addition to the assay plate (Evotec
TM 384-well
microplate, Germany), 20,000 L. major promastigote parasites from
an exponential phase culture (,10
7 parasites/mL) were diluted in
M199, seeded in 50 mL per well using FlexDrop
TM and incubated
at 28uC for 28 hours, followed by the addition of 5 mM resazurin
sodium salt (Sigma R7017, United States) and further incubation
for 20 hours at 28uC. After a 48-hour exposure to compounds, the
reference drug (EtBr) or control (1% DMSO), the parasites were
fixed with 2% paraformaldehyde (PFA) and plates were read in
Victor3
TM (Perkin Elmer) at 530 nm (excitation) and 590 nm
(emission). This fixation step is not necessary for resazurin readout,
but allows flexibility in the automation schedule and increases
assay robustness by decreasing metabolic variability between
populations across wells and plates. Z-factor, calculated as
12(36sp+36sn)/(|mp2mn|), where mp, sp, mn and sn are the
means (m) and standard deviations (s) of both the positive (p) and
negative (n) controls [15], and other parameters, including DRC
plates for verification of the reference drug EC50 (accepted if
within the range of 36higher or lower than a defined value from
the literature), coefficient of variation not higher than 10% in the
controls and edge effect evaluation, were used for screening
validation and hits selection.
Secondary Screening Assay: Human Cell Toxicity Test
To assess the cytotoxicity of compounds on THP-1, an acute
monocytic leukemia-derived human cell line (ATCC TIB-202
TM),
a viability assay also using resazurin reduction with minor
modifications in concentration and incubation time was per-
formed. Z-factor [15] and other parameters [16] were used for
secondary screening validation and hit exclusion.
Macrophage Infection and Intracellular Amastigotes
Assay for Hit Confirmation
THP-1 cells were cultivated in suspension at a density of 10
5 to
10
6 cells/mL in RPMI (Gibco 1640, United States) medium
supplemented with 10% heat-inactivated FBS and 1% streptomy-
cin/penicillin at 37uC and 5% CO2. The differentiation of THP-1
into macrophages was induced by incubation of the cells for
48 hours with phorbol 12-myristate 13-acetate (PMA) at 50 ng/
ml. For infection, late-stage L. major or L. donovani rich in
metacyclic promastigotes was added to differentiated THP-1 cells
(ratio of 50 parasites to 1 host cell) in Evotec
TM 384-well
microplates using a FlexDrop
TM (Perkin Elmer) to dispense
50 mL/well. Compounds were added 24 hours after infection
Author Summary
Every year, more than 2 million people worldwide suffer
from leishmaniasis, a neglected tropical disease present in
88 countries. The disease is caused by the single-celled
protozoan parasite species of the genus Leishmania, which
is transmitted to humans by the bite of the sandfly. The
disease manifests itself in a broad range of symptoms, and
its most virulent form, named visceral leishmaniasis, is
lethal if not treated. Most of the few available treatments
for leishmaniasis were developed decades ago and are
often toxic, sometimes even leading to the patient’s death.
Furthermore, the parasite is developing resistance to
available drugs, making the discovery and development
of new antileishmanials an urgent need. To tackle this
problem, the authors of this study employed the use of
high-throughput technologies to screen a large library of
small, synthetic molecules for their ability to interfere with
the viability of Leishmania parasites. This study resulted in
the discovery of two novel compounds with leishmanicidal
properties and promising drug-like properties, bringing
new candidates to the leishmaniasis drug discovery
pipeline.
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Amphotericin B as the reference compound (positive control) at
10 mM as the EC100 and 1% DMSO (negative control) were used
in all the plates for data normalization (see bellow). After 4 days of
incubation, remaining free promastigotes were removed by
washing five times with PBS and cells were simultaneously fixed
with 2% PFA and the DNA stained with 5 mM of Draq5 (Biostatus
DR50200, England). Microplates were read in an Opera confocal
microscope (Perkin Elmer), enabling the determination of the
infection ratio of the parasites by image analysis. An algorithm was
developed to identify and individualize the macrophages by setting
an intensity threshold to discriminate background (extracellular
space) from foreground (macrophage cells area). The macrophage
nuclei and internalized parasites were identified and counted if
localized in the foreground previously selected (Figure S1). With
this technique, extracellular parasites were not considered in the
calculations, and the infection ratio was determined by the
number of infected cells divided by the total number of cells after
normalization based on the controls. The average infection ratios
from the positive and negative controls were normalized to 0%
and 100% infection, and the infection ratio read from each
compound activity was proportionally distributed within this
range. Z-factor [15] was used for protocol validation and active
compound selection acceptance.
Microsomal Stability Assay
Compounds at a concentration of 2 mMi n0 . 2 %D M S Ow e r e
incubated with 0.5 mg/mL rat (Sprague-Dawley Rat, BD
Gentest) and human (human pool donors, BD Gentest) liver
microsomes in potassium phosphate buffer in a reaction started
by the addition of NADPH and stopped either immediately or at
5, 10, 30, 60 or 120 minutes for a precise estimate of microsomal
stability. The corresponding loss of the parent compound was
determined by a quadrupole liquid chromatography-mass
spectrometry (LC-MS) with diode-array detection (Agilent
1200, Agilent Technology). The samples were passed through
trapping cartridges (Security Guard Cartridge, Gemini C18,
462.0 mm, 3 mm, Phenomenex) followed by an analytical
column (Gemini C18, 5062.0 mm, 3 mm, Phenomenex). Positive
electrospray ionization (ESI+) was employed for this analysis. The
mobile phases A (water with 0.1% formic acid) and B (acetonitrile
with 0.1% formic acid) were used at a flow rate of 0.3 mL/min.
Gradient elution started with 95% mobile phase A and 5%
mobile phase B. Elution was changed to a linear gradient until
Figure 1. HTS assay validation. A) Linear correlation between relative fluorescence unit (RFU) readings from resazurin reduction (y-axis) and
parasite number from microscopy counting (x-axis). B) Dose response curve and EC50 (black line for L. major and grey dashed line for L. donovani)o f
the reference compounds used as controls: EtBr, amphotericin B, miltefosine and paromomycin. C) Distribution of 33 control microplates showing 1%
DMSO as the negative control (blue dots), EtBr EC50-30 nM (black dots) and EtBr EC100-10 mM as positive controls (yellow dots) and the Z-factor of
0.62. D) Distribution plot of the duplicate assay screen of 4,000 compounds (red dots) and controls in three different concentrations, following the
same color standards as in C.
doi:10.1371/journal.pntd.0000675.g001
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then increased to 95% B over 0.5 min, and held for 1.5 min.
Then, the elution gradient returned to 95% A and 5% B over
0.5 min, was held for the remaining 3.5 min. The percentage of
the remaining compound was calculated by comparison with the
initial quantity at 0 min. Half-life was calculated based on first-
order reaction kinetics.
CYP450 Inhibition Assays
Individual fluorescent probe substrates were used with indi-
vidual rhCYP isozymes and fluorescence detection according to a
previously published method [17]. Probe substrates were 7-
benzyloxy-4-(trifluoromethyl)-coumarin (BFC) for CYP3A4 and 3-
[2-(N,N-diethyl-N-methylammonium)ethyl]-7-methoxy-4-methylcou-
marin (AMMC) for CYP2D6 in 0.5% DMSO. IC50 was determined
using an eight-point concentration curve with three-fold serial
dilutions. Victor3
TM (Perkin Elmer) was used for quantification in
the fluorescent method (Perkin Elmer Life and Analytical Sciences).
Results
HTS Assay Development and Validation
The effect of compounds on Leishmania viability was assessed by
fluorometric measurement of resazurin reduction [13]. Equiva-
lence between the fluorescence signal from resazurin reduction
and the number of parasites was confirmed by the linear
correlation between parasites counted by light microscopy and
the relative fluorescence unit (RFU) value measured (Fig. 1A).
Reference compounds for antileishmanial activity (EtBr, ampho-
tericin B, miltefosine and paromomycin) were tested (Fig. 1B) as a
step of the validation process. Values obtained for these
compounds in our assay in HTS format were similar to those
classically reported for these drugs [18,19]. Assay validation was
performed on three separate days using 33 microplates (384
wells/plate) containing only controls. Variability between well-to-
well, plate-to-plate and day-to-day were measured to confirm
assay robustness, resulting in a Z-factor of 0.62 (Fig. 1C). After
assay validation, we screened a 4,000-compound library contain-
ing a number of compounds with known pharmacological
properties. The screen was performed using three different
concentrations with 106dilution factors for each compound with
the highest concentration in the range of 2–20 mM, as
compounds in the library did not all have the same molarity.
This assay was done in duplicate and results of each
concentration assay are represented as individual graphs in Fig.
1D. A 70% proliferation inhibition of the parasites from the
lowest compound concentration (0.2–0.02 mM) was the cut-off
used for active compound selection. The list of active chemicals
included, but was not limited to, previously reported antileish-
manial compounds: anisomycin [20], pentamidine isethionate
[21], berberine chloride [22], parthenolide [23], nitrofural [24],
furazolidone [24] and nifurtimox [25] (data not shown). These
results were considered a pharmacological validation of the assay,
confirming the ability of the assay to identify antileishmanial
compounds.
HTS
A library containing 26,500 structurally diverse chemical
compounds was screened at 10 mM against L. major. The positive
(EC100) and negative controls (1% DMSO) provided a Z-factor of
0.80 (Fig. 2A). The 70% growth inhibition cut-off criterion was
used to select the most active compounds. The frequency map
distribution based on binned RFUs highlights the distinction of
two groups of compounds, in which ,97% were in the non-active
group with RFUs higher than 201,600. Another group contained
,2% (567 compounds) with RFUs lower than 105,500,
representing the active compounds (Fig. 2B). The remaining
,1% were situated between the other 2 groups and were not
sufficiently active for selection.
To exclude potentially toxic compounds from the active list, we
performed a secondary viability screening using the non-
differentiated human macrophage cell line THP-1. Compounds
Figure 2. Antileishmanial HTS with 26,500 compounds. A)
Distribution plot of the 26,500 compounds (red dots), 1% DMSO (blue
dots), EC100 (yellow dots) and Z-factor=0.80. B) Frequency distribution
of the 26,500 compounds based on binned RFUs, highlighting active
compound selection with a black dashed box. Data for reference
compound EC100 in yellow, for reference compound EC50 in black and
for the 26,500 compounds in red. C) A funnel representing selection of
antileishmanial activity from 26,500 compounds to 124 hit compounds
after primary screening (antileishmanial activity against promastigotes),
secondary screening (toxicity exclusion) and no redundancy against
Mycobacterium tuberculosis or HIV screenings done in-house.
doi:10.1371/journal.pntd.0000675.g002
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or lower were discarded. In addition, compounds that were found
to be active in other in-house, anti-infective HTS campaigns were
also excluded to avoid non-specific mechanisms of action. This
cytotoxicity determination and Leishmania specificity filter resulted
in a list of 124 active compounds (Fig. 2C).
Antileishmanial Activity Confirmation on Intracellular
Amastigotes
Infection of human macrophage cells in vitro with Leishmania has
been previously described as a suitable model for screening [26]
and was adopted for our purpose. The 124 active compounds
selected from the secondary assay were tested in 10-point dose
response with 2-fold serial dilutions starting from 20 mM against
promastigotes and intracellular amastigotes of L. major and L.
donovani infecting macrophages. The average Z-factor calculated
per plate based on the reference drug (amphotericin B) and carrier
(1% DMSO) was 0.62 for L. major infection and 0.59 for L. donovani
infection, and minimum accepted Z-factor for the analysis was 0.5.
The amphotericin B EC50 for L. major infecting macrophages was
1.06 mM and EC50 for L. donovani infecting macrophages was
0.82 mM. From the tested compounds, 5 exhibited activity against
L. major intracellular amastigotes and are presented in Table 1.
Activity confirmation was based on elimination or growth
inhibition of both promastigotes and intracellular amastigotes
(parasite forms) of L. major and L. donovani. Differences between
promastigote and intracellular amastigote forms regarding com-
pound susceptibility were demonstrated, as shown in Figure S2.
Based on the methods applied, for both L. major and L. donovani all
the compounds, except CA272 for L. major, showed more potency
against the extracellular form of the parasite (Figure S2).
When comparing species sensitivity we found that some
compounds caused different responses in different species.
TE122, for example, was only active against the intracellular L.
major but showed no activity against intracellular L. donovani up to
20 mM, as shown in Table 1 and Figure S2. This different drug
sensitivity within Leishmania species is already known [27] and must
be considered in future therapy development.
Using controls with carrier (1% DMSO) and 10 mM ampho-
tericin B (EC100 concentration) (Fig. 3A), the two most active
compounds, CH872 and CA272 (Fig. 3B), were selected based on
image analysis (for details, see Figure S1). These compounds
showed significant reduction of macrophage infection with L. major
after four days incubation (Fig. 3D, E). Moreover, after phenotypic
evaluation of the macrophages post-treatment, the compound
activity was not due to toxic effects on host cells. Figs. 3C and 3D
show, respectively, the infection exposed to a sub-optimal
concentration (1 nM) and one example of active concentrations
of the compounds (0.7 mM for CH872 and 10 mM for and CA272)
according to infection reduction. The dose-response curves against
intracellular L. major of both compounds plotted in Fig. 3E resulted
in a calculated EC50 of 0.3 mM for compound CH872 and 0.8 mM
for CA272. Only these compounds showed EC50s against
intracellular L. major lower than 1 mM and a ratio CC50/EC50
(L. major) greater than 10 and were selected for further
characterization.
In vitro Metabolic Stability Assays
The metabolic stability of the selected compounds in the
presence of human and rat liver microsomes was assessed.
Compound CH872 was stable in the presence of human liver
microsomes, with 99.6% of the parent compound remaining after
30 minutes and a long theoretical half-life. However, it was
unstable in rat liver microsomes, being completely degraded after
25 minutes, giving a theoretical half-life of 4.1 minutes (Fig. 4). For
CA272, 77.8% of the parent compound remained after 30 minutes
in the presence of human liver microsomes, with a theoretical half-
life of 79.4 minutes, whereas 53.3% of the parent compound
remained in the presence of rat liver microsomes, with a
theoretical half-life of 31.8 minutes (Fig. 4). The species difference
is most likely due to different enzyme compositions of the liver
microsomes. These differences will have to be taken into account if
these compounds are to be used with in vivo pharmacokinetic
models, which are typically performed in rats.
In vitro CYP Inhibition Assays
CYP is a large superfamily of enzymes involved in numerous
biological processes [28]. Member of the families CYP2 and CYP3
have a role in drug and steroid metabolism. Toxic side effects as
well as drug-drug interactions may be predicted by testing the in
vitro inhibition of these CYPs by chemical compounds [29].
CYP3A4 and CYP2D6 inhibition assays were performed with
both compounds. Whereas CH872 did not inhibit CYP3A4
(EC50&10 mM) or CYP2D6 (EC50.10 mM), CA272 did inhibit
CYP3A4 with an EC50 of 3.41 mM, but did not inhibit CYP2D6
(EC50&10 mM), as shown in Table 2.
Discussion
A high-throughput screening assay for the identification of
antileishmanial compounds was developed involving a two-step
strategy: primary screening using promastigotes in a 384-well plate
format and secondary screening of active compounds using
intracellular amastigotes. The primary screening was validated
on a robust statistical basis (Fig. 1C) and was demonstrated to be
able to identify known antileishmanial compounds when a library
of known bioactive small molecules was screened as a proof of
principle. This assay was then applied to a screen of 26,500
Table 1. Active compounds against intracellular L.major.
L. major L. donovani Cytotoxicity CC50 THP-1
Compound code EC50 promastigote EC50 amastigote EC50 promastigote EC50 amastigote
CH872 0.1 mM0 . 3 mM 0.05 mM 0.06 mM .10.0 mM
CA272 2.7 mM0 . 8 mM 2.7 mM 19.0 mM .10.0 mM
NJ231 0.8 mM 11.0 mM 0.6 mM .20.0 mM .10.0 mM
CG170 1.0 mM8 . 0 mM 0.1 mM 14.0 mM .10.0 mM
TE122 7.8 mM 12.0 mM 3.0 mM &20.0 mM .10.0 mM
doi:10.1371/journal.pntd.0000675.t001
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compounds (567) inhibited parasite growth by at least 70% after
48 hours of compound exposure. From these active compounds,
almost 80% were excluded due to cytotoxicity or lack of specificity
(data not shown), resulting in 124 compounds that were tested
against the amastigote in an infection assay with a human
macrophage cell line. Although the clinically relevant stage of the
Leishmania parasites is the intracellular amastigote, the extracellular
Figure 3. CH872 and CA272 antileishmanial activity against intracellular L. major amastigotes. A) Infected THP-1 cells in the presence of
1% DMSO as a negative control (left) and EC100 obtained with 10 mM of amphotericin B as a positive control (right). B) Structures of CH872 (left) and
CA272 (right). C) Infected THP-1 cells in the presence of 1 nM of CH872 (left) and 1 nM of CA272 (right) as non-active concentrations of the
compounds and D) in the presence of 0.7 mM of CH872 (left) and 10 mM of CA272 (right) as effective concentrations from the dose-response curves.
E) Dose-response curves of the compounds CH872 and CA272 plotting the infection ratio (continuous lines) and relative number of parasites
compared to the DMSO control (dashed lines).
doi:10.1371/journal.pntd.0000675.g003
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cheaper to handle in the large scale required by HTS. Besides,
promastigotes and amastigotes share common metabolic machin-
ery and pathways, and targets against the first form could be
relevant against the second one. This screening strategy against
promastigotes was applied by St. George et al. to screen 15,000
compounds against L. tarentolae [30] and recently by Sharlow et al.
to investigate 200,000 unique compounds for L. major growth
inhibition [31]. As discussed by the authors of the latter study, the
use of the promastigote stage for antileishmanial drug discovery
may compromise the discovery of macrophage-metabolized
prodrugs, such as antimonials. In the present study, antileishma-
nial activity of the primary selected compounds was further
confirmed against intracellular L. donovani amastigotes in a cellular
image-based assay in which host cell integrity was taken into
account. Although this strategy does not compensate for the
possibility of missing prodrugs during the primary screening, it
does guarantee that the active compounds are able to cross the
macrophage membrane and kill the amastigotes inside the host
cells.
As expected, most of the compounds were less active or not
active against the intracellular amastigote form when compared to
the promastigote, as shown in Table 1 and Figure S2. To be active
against the amastigote, a compound must cross two membrane
barriers (cellular membrane of the macrophage and phagolyso-
some vacuole membrane) and maintain stability under low pH
and in the presence of free radicals in the phagolysosome
environment, which increase the attrition rate compared to the
promastigote assay. However, in the promastigote extracellular
assay, the parasite is directly exposed to the compound.
Furthermore, the concentrations at which compounds show
activity do not have an observed effect on the macrophage host
cell, confirmed by both a cytotoxicity test and image analysis.
One of the two most active hit compounds was the hydrazine
CA272, a novel scaffold for antileishmanial compounds. It
exhibited good efficacy in L. major infection reduction, although
the activity against the intracellular L. donovani amastigote was
lower. Other unfavorable properties, such as low metabolic
stability against human liver microsomes (Fig. 4) and inhibition
of CYP3A4 (Table 2), might be improved by the optimization of
the two phenyl rings, which can be easily modified. Tests against
other Leishmania species should also be considered for further
studies. Satisfactory activity against intracellular L. major,i n
addition to low toxicity, indicates a good starting point for a
new antileishmanial candidate drug.
The most active compound, CH872, is of interest due to its high
in vitro activity and lack of cytotoxicity (Fig. 3, Table 1 and Figure
S2), along with favorable metabolic stability and CYP inhibition
data (Table 2). Additionally, its core structure, 4-hydroxyquino-
line, is a novel scaffold for antileshmanial inhibition. Several
modifications of quinolines have been carried out to obtain
antileishmanials, such as sitamaquine or quinoline derivatives with
side-chains at C4 or at phenyl rings [32,33]; however, none of
these modifications produced 4-hydroxyquinoline derivatives.
Sitamaquine is in clinical trials (Phase II), and no other quinoline
derivatives have been approved as antileishmanial drugs. Some
issues reported from this class of compounds include kidney
toxicity, which can be lethal [34]. Unlike other antileishmanial
quinoline derivatives, compound CH872 contains a 4-OH group,
which allows this compound to equilibrate with its tautomer
CH872A (Fig. 5). Studies directed toward establishing the
structure-activity relationships (SARs) and defining the mode of
action of CH872 are currently underway.
The identification of these two antileishmanial compounds
demonstrates that primary screening against the promastigote
form can be used to identify novel scaffolds that can serve as the
starting point for hit-to-lead programs. Using the experience
gained in this effort, we are currently developing and implement-
ing an automated high-throughput drug screening assay in 384-
well plate format using amastigotes infecting human macrophages
as a primary screening assay.
In summary, high-throughput screening of small molecule
libraries against promastigotes in a rapid and simple 384-well plate
format assay is able to identify novel antileishmanial compounds.
Furthermore, these novel compounds have been shown to be
active against the intracellular amastigote. As the promastigote
screening is much easier and cheaper compared to screening the
intracellular amastigote, this strategy could be used to screen
libraries of natural compounds commonly available in endemic
areas, where resources are often limited. This opens new
opportunities for the discovery of future candidates for drug
development to be performed locally in endemic countries.
Figure 4. CH872 and CA272 stability in the presence of liver
microsomes. Disappearance of CH872 and CA272 in the presence of
human (lines) and rat (dashed lines) liver microsomes.
doi:10.1371/journal.pntd.0000675.g004
Table 2. Determination of IC50 (mM) of individual human
P450s for lead compounds.
Compound CYP3A4 CYP2D6
CH872 .10 .10
CA272 3.41 .10
Ketoconazole 0.05 –
Quinidine – 0.02
doi:10.1371/journal.pntd.0000675.t002
Figure 5. New quinoline with antileishmanial activity. Unlike
other quinoline derivatives reported as antileishmanial compounds,
CH872 contains a 4-OH group that allows this compound to equilibrate
with its tautomer (CH872A). 8-Cl can facilitate the tautomerization by
making a H-bond with the NH in CH872A.
doi:10.1371/journal.pntd.0000675.g005
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Figure S1 Macrophage infection detection: software interface.
THP-1 macrophages infected with L. donovani amastigotes were
fixed and stained with Draq5, and pictures were acquired in the
Opera confocal platform as described in the Methods section. A)
Raw images (left) are analyzed by the algorithm, which will
attribute colors masks (right) to highlight elements detected during
the analysis: THP-1 cytoplasm in blue, THP-1 nuclei in red and
parasites in green. B) Zoomed detail of the area marked in a red
square in (A) showing a non-infected and an infected THP-1 cell
before (left) and after (right) the algorithm has been applied to
identify intra- and extracellular parasites Note that all parasites
identified by the software are highlighted with a cross (+). Green
arrows show examples of intra- and extracellular parasites that are,
respectively, counted and not counted for infection ratio
calculations.
Found at: doi:10.1371/journal.pntd.0000675.s001 (1.85 MB TIF)
Figure S2 Dose Response Curves (DRCs) of the 24 most active
compounds against L. major promastigotes. The first 5 compounds
(CH872, CA272, NJ231, CG170 and TE122) are presented in
Table 1. Black curves refer to activity against promastigotes and
blue curves refer to activity against intracellular amastigotes.
Continuous black or blue curves refer to L. major while dashed
curves refer to L. donovani. Antileishmanial compound activity is
shown on the left Y axis after normalization relative to negative
control (0% activity - no drug exposure) and positive control
(100% activity - EC100 of the reference drug). The red curves
represent the number of THP-1 cells shown in the right Y axis,
demonstrating no cytotoxicity effect up to 10 mM of compound
exposure (maximal concentration of compound compatible with
the assay format).
Found at: doi:10.1371/journal.pntd.0000675.s002 (0.47 MB TIF)
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